dasatinib
Dasatinib is a potent second-generation tyrosine kinase inhibitor that targets BCR-ABL and Src family kinases. While primarily used as an antineoplastic agent for Philadelphia chromosome-positive leukemias, it is increasingly studied in longevity research as a senolytic due to its ability to selectively induce apoptosis in senescent cells.
Lab Notes — Research Studies
01 Dasatinib and Quercetin as Senolytic Drugs Improve Fat Deposition and Exhibit Antifibrotic Effects in the Medaka Metabolic Dysfunction-Associated Steatotic Liver Disease Model
This study demonstrates that the combination of dasatinib and quercetin effectively removes senescent cells, reduces liver fat deposition, and provides anti-fibrotic benefits.
View Study ((PubMed))02 Emerging use of senolytics and senomorphics against aging and chronic diseases
A review of how dasatinib acts as a senolytic to eliminate cells in cycle arrest, potentially treating age-related disorders like atherosclerosis and type 2 diabetes.
View Study ((PubMed))03 Real‐World Outcomes With Low‐Dose Dasatinib (50 mg) in Imatinib-Resistant Chronic Myeloid Leukemia
Research indicates that a lower dose of 50mg may maintain clinical efficacy while significantly improving the safety profile compared to the standard 100mg dose.
View Study ((PubMed))04 Drugs induced pulmonary arterial hypertension
This paper identifies dasatinib as a known risk factor for developing severe pulmonary arterial hypertension, which is often reversible upon cessation of the drug.
View Study ((PubMed))05 Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism
Study findings suggest that common flavonoids like apigenin can significantly alter the plasma concentration and bioavailability of dasatinib through metabolic interactions.
View Study ((PubMed))Formula — Benefits & Dosage
⚗️ Effects
- Synergistic Action: Most effective as a longevity tool when combined with Quercetin (the D+Q protocol) to broaden the range of targeted senescent cells.
- Intermittent Efficacy: Unlike daily supplements, it is frequently used in 'pulses' to clear cells without constant systemic exposure.
- Disease Management: Highly effective for imatinib-resistant leukemia, showing deep molecular responses.
💉 Dosage & Administration
- Senolytic Protocol: Common off-label longevity dosage is 100mg taken once weekly or for 2-3 consecutive days once a month.
- Standard Clinical Dose: For leukemia, the approved dose is 100mg daily, though 50mg is increasingly studied for better tolerance.
- Pulse Frequency: Longevity enthusiasts often debate between monthly vs. quarterly cycles to allow for healthy cell recovery.
⚠️ Side Effects
- Fluid Retention: Risk of pleural effusion (fluid around the lungs) and peripheral edema even at lower doses.
- Hematologic Stress: Potential for myelosuppression, including temporary drops in white blood cell and platelet counts.
- Pulmonary Hypertension: A rare but serious risk of increased blood pressure in the lung arteries.
- Gastrointestinal Distress: Nausea and hemorrhagic colitis have been reported in clinical settings.
📦 Availability & Sourcing
- Prescription Only: Heavily regulated as a chemotherapy agent, requiring strict medical supervision.
- High Cost: Traditional pharmaceutical versions are extremely expensive, leading longevity users to seek specialized sourcing or clinical trials.
Reaction Log — User Experiences
Users are highly optimistic about its powerful senolytic 'age-reversal' potential, but the community is deeply cautious due to its profile as a high-potency chemotherapy drug with serious systemic risks.
Synthesis — Related Compounds
⚠️ IMPORTANT DISCLAIMER
This information is for educational and research purposes only. dasatinib may not be approved for human use. Always consult a qualified healthcare professional before using any supplements or research compounds. We do not guarantee accuracy or completeness of information presented.